Novavax says COVID-19 shot 80% effective in adolescent study
Novavax Inc (NVAX.O) said its two-dose vaccine was 80% effective against COVID-19 in a late-stage trial testing the shot in teens aged 12 to 17 years. The trial involved 2,247…
Promoting quality and affordable healthcare in support of Government agenda
